Skip to main content
AQST
NASDAQ Life Sciences

Aquestive Therapeutics Announces Chief Legal Officer Transition and New Appointment

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$3.92
Mkt Cap
$495.503M
52W Low
$2.12
52W High
$7.55
52W Position info
85% above low
Off High info
48% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

AQST sits 85% above its 52-week low of $2.12.

Summary

Aquestive Therapeutics announced a change in its Chief Legal Officer and Chief Compliance Officer roles, with Lori J. Braender stepping down and Thomas A. Zalewski appointed as her successor, accompanied by a significant equity vesting for the departing officer.


Key Events · Executive and Board Changes · AQST

  • Executive Departure

    Lori J. Braender is stepping down as Chief Legal Officer and Chief Compliance Officer, effective April 2, 2026, but will remain as Corporate Secretary.

  • Significant Equity Vesting

    Ms. Braender will receive full and immediate vesting of all unvested stock options, RSUs, SARs, and other equity awards on May 7, 2026, as part of her separation agreement.

  • New Executive Appointment

    Thomas A. Zalewski has been appointed as the new Chief Legal Officer and Chief Compliance Officer, effective April 2, 2026, bringing extensive experience in life sciences law.

  • Inducement Equity Grant

    Mr. Zalewski will receive an inducement grant of 100,000 Restricted Stock Units and 75,000 non-qualified common stock options, vesting over three years.


Analysis · AQST · Life Sciences

Aquestive Therapeutics is undergoing a significant leadership transition with the departure of its Chief Legal Officer and Chief Compliance Officer, Lori J. Braender, from her executive roles. The immediate vesting of all her unvested equity awards as part of her separation package represents a notable compensation event for the company. The appointment of Thomas A. Zalewski as the new Chief Legal Officer and Chief Compliance Officer provides continuity in a critical function, especially as the company navigates recent FDA approval delays and increased net losses.

At the time of this filing, AQST was trading at $3.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $495.5M. The 52-week trading range was $2.12 to $7.55. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AQST - Latest Insights

AQST
May 13, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.75
Real-time Price: $3.75 info
Change: -$1.00 (-21%) info
Market Cap: $471.756M info
AQST
May 13, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.84
Real-time Price: $3.75 info
Change: -$1.09 (-22%) info
Market Cap: $471.756M info
AQST
May 13, 2026, 4:01 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.32
Real-time Price: $3.75 info
Change: -$0.570 (-13%) info
Market Cap: $471.756M info
AQST
Apr 24, 2026, 5:00 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $4.06
Real-time Price: $3.75 info
Change: -$0.3112 (-8%) info
Market Cap: $471.756M info
AQST
Mar 30, 2026, 7:44 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.05
Real-time Price: $3.75 info
Change: -$0.300 (-7%) info
Market Cap: $471.756M info